Evidence review
What trials such as STEP 4 show about weight regain after stopping semaglutide, and what it means for long-term GLP-1 planning.
Released: · Last reviewed:
Evidence shows many people regain a substantial portion of lost weight after stopping GLP-1 therapy. In STEP 4 (JAMA 2021), participants who switched to placebo regained much of their loss over the following year, while those who continued largely maintained it. GLP-1 therapy is generally a long-term treatment.
Educational use only. This article is for educational purposes only and does not provide medical advice. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products and should only be prescribed when clinically appropriate by a licensed healthcare provider.
After an initial semaglutide phase, participants were randomized to continue or switch to placebo. The continuation group maintained weight loss; the placebo group regained a large share — underscoring obesity as a chronic condition needing ongoing management.
Because stopping often leads to regain, discuss a sustainable plan — including cost and continuity — with your clinician before starting. Predictable long-term pricing matters; compare via the our October 2026 price index reference.
Trials such as STEP 4 show substantial regain after stopping, while continued treatment maintains loss; plan long-term with your clinician.
It is generally a long-term treatment for a chronic condition; duration is an individual clinical decision.